Development of two primary malignant melanomas after treatment with adalimumab: A case report and review of the possible link between biological therapy with TNF-α antagonists and melanocytic proliferation

Dermatology

Volumn 221, Issue 1, 2010, Pages 9-12

  Katoulis, A C ^a   Kanelleas, A ^a   Zambacos, G ^a   Panayiotides, I ^a   Stavrianeas, N G ^a  

^a UNIVERSITY OF ATHENS   (Greece)

Author keywords

Adalimumab; Biological therapy; Eruptive melanocytic nevi; Immunosuppression; Malignant melanoma; TNF antagonist

Indexed keywords

ADALIMUMAB; METHOTREXATE;

AGED; ANAMNESIS; ARTICLE; BIOLOGICAL THERAPY; CANCER STAGING; CASE REPORT; CELL PROLIFERATION; COMPUTER ASSISTED TOMOGRAPHY; DRUG WITHDRAWAL; EXCISION; FOLLOW UP; HISTOPATHOLOGY; HUMAN; MALE; MELANOCYTE; MELANOCYTIC NEVUS; MELANOMA; METASTASIS; PRIMARY TUMOR; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SCALP; SENTINEL LYMPH NODE; SKIN DEFECT; SKIN NODULE; SKIN PIGMENTATION; TREATMENT DURATION;

AGED; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CELL PROLIFERATION; HUMANS; LEG; MALE; MELANOCYTES; MELANOMA; METHOTREXATE; SCALP; SKIN NEOPLASMS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77955712243     PISSN: 10188665     EISSN: None     Source Type: Journal    
DOI: 10.1159/000300136     Document Type: Article

References (24)

1. Naldi L: Malignancy concerns with psoriasis treatments using phototherapy, methotrexate, cyclosporin, and biologics: fact and controversies. Clin Dermatol 2010; 28: 88-92.
2. Mease PJ: Adalimumab: an anti-TNF agent for the treatment of psoriatic arthritis. Expert Opin Biol Ther 2005; 5: 1491-1504.
3. Chaudhari U, Romano P, Mulcahy LD, et al: Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomized trial. Lancet 2001; 357: 1842-1847.
4. Gordon KB, Blum RR, Papp KA, et al: Efficacy and safety of adalimumab treatment in patients with moderate-to-severe psoriasis: a double-blind, randomized clinical trial. Psoriasis Forum 2007; 13: 4-11.
5. Gottlieb AB, Leonardi CL, Goffe BS, et al: Etanercept monotherapy in patients with psoriasis: a summary of safety, based on an integrated multistudy database. J Am Acad Dermatol 2006; 54:S92-S100.
6. Bongarzt T, Sutton AJ, Sweeting MJ, et al: Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006; 295: 2275-2285.
7. Descotes J, Gouraud A: Clinical immunotoxicity of therapeutic proteins. Expert Opin Drug Metab Toxicol 2008; 4: 1537-1549.
8. Tyring S, Gordon KB, Poulin Y, et al: Long term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis. Arch Dermatol 2007; 143: 719-726.
9. Brown SL, Greene MH, Gershon SK, et al: Tumor necrosis factor antagonist therapy and lymphoma development. Arthritis Rheum 2002; 46: 3151-3158.
10. Askling J, Fored SM, Baecklund E, et al: Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumor necrosis factor antagonists. Ann Rheum Dis 2005; 64: 1414-1420.
11. Chakravarty EF, Michaud K, Wolfe F: Skin cancer, rheumatoid arthritis, and tumor necrosis factor inhibitors. J Rheumatol 2005; 32: 2130-2135.
12. Fryrear RS 2nd, Wiggins AK, Sanguenza O, Yosipovitch G: Rapid onset of cutaneous squamous cell carcinoma of the penis in a patient with psoriasis on etanercept therapy. J Am Acad Dermatol 2004; 51: 1026.
13. Euvrad S, Kanitakis J, Claudy A: Skin cancers after organ transplantation. N Engl J Med 2003; 348: 1681-1691.
14. Alaibac M, Piaserico S, Rossi CR, et al: Eruptive melanocytic naevi in patients with renal allografts: report of 10 cases with dermoscopic findings. J Am Acad Dermatol 2003; 49: 1020-1022
15. Bauer JW, Schaeppi H, Kaserer C, et al: Large melanocytic nevi in hereditary epidermolysis bullosa. J Am Acad Dermatol 2001; 44: 577-584.
16. Shoji T, Cockerell CJ, Koff AB, et al: Eruptive melanocytic nevi after Stevens-Johnson syndrome. J Am Acad Dermatol 1997; 37: 337-339.
17. Bovenschen HJ, Tjioe M, Vermaat H, et al: Induction of eruptive benign melanocytic naevi by immune suppressive agents, including biological. Br J Dermatol 2006; 154: 880-884.
18. Katsanos KH, Christodoulou DK, Zioga A, et al: Cutaneous nevi pigmentosus during infliximab therapy in a patient with Crohn's disease: fallacy or coincidence? Inflamm Bowel Dis 2003; 9: 279.
19. Woodhouse J, Maytin EV: Eruptive nevi of the palms and soles. J Am Acad Dermatol 2005; 52:S96-S100.
20. Richert S, Bloom EJ, Flynn K, et al: Widespread eruptive dermal and atypical melanocytic nevi in association with chronic myelocytic leukemia: case report and review of the literature. J Am Acad Dermatol 1996; 35: 326-329.
21. Fulchiero GJ Jr, Salvaggio H, Drabick JJ, et al: Eruptive latent metastatic melanomas after initiation of antitumor necrosis factor therapies. J Am Acad Dermatol 2007; 56:S65-S67.
22. Kowalzick L, Eickenscheidt L, Komar M, Schaarschmidt E: Long term treatment of psoriasis with TNF-alpha antagonists: occurrence of malignant melanoma. Hautarzt 2009; 608: 655-657.
23. Gordon KB, Langley RG, Leonardi C, et al: Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study. J Am Acad Dermatol 2006; 55: 598-606.
24. Khan I, Rahman L, McKenna DB: Primary cutaneous melanoma: a complication of infliximab treatment? Clin Exp Dermatol 2009; 34: 524-526.